Bristol Myers (NYSE: BMY) director adds 3,996 deferred share units in Form 4 filing

Rhea-AI Filing Summary

Bristol Myers Squibb director Phyllis R. Yale received 3,996.367 Deferred Share Units on February 1, 2026 at a reference price of $55.05 per unit. These derivative awards increase her holdings of Deferred Share Units to 43,326.695, all held directly.

Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when she ceases to be a director or at a future date she previously specified, and reflect deferred compensation and reinvested dividends under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider YALE PHYLLIS R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	3,996.367	$55.05	$220K

Holdings After Transaction: Deferred Share Units — 43,326.695 shares (Direct)

Footnotes (1)

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YALE PHYLLIS R

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	02/01/2026		A		3,996.367		(1)	(1)	Common Stock, $0.10 par value	3,996.367	$55.05	43,326.695(2)	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Phyllis R. Yale	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bristol Myers Squibb (BMY) director Phyllis R. Yale report in this Form 4?

Phyllis R. Yale reported an award of 3,996.367 Deferred Share Units on February 1, 2026. These units are part of her deferred director compensation and increased her total Deferred Share Unit holdings to 43,326.695, all reported as directly owned.

How do the Deferred Share Units reported by BMY director Phyllis R. Yale work?

Each Deferred Share Unit will convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when she ceases to be a director or at a previously specified future date under the deferred compensation plan.

What is the reference price for the Deferred Share Units granted to BMY director Phyllis R. Yale?

The 3,996.367 Deferred Share Units were reported with a reference price of $55.05 per unit. This price is used for reporting purposes in the Form 4 and reflects the value assigned at the time of the compensation award.

How many Deferred Share Units does BMY director Phyllis R. Yale own after this transaction?

After the February 1, 2026 award, Phyllis R. Yale beneficially owns 43,326.695 Deferred Share Units. All of these derivative securities are reported as held directly, linked to her service as a non-employee director at Bristol Myers Squibb.

What plan governs the Deferred Share Units reported by Bristol Myers Squibb (BMY) director Phyllis R. Yale?

The Deferred Share Units are tied to the 1987 Deferred Compensation Plan for Non-Employee Directors. This plan allows director compensation and related dividends to be deferred and reinvested, accumulating as units that later convert into Bristol Myers Squibb common stock.

When will Phyllis R. Yale’s BMY Deferred Share Units be settled into common stock?

The Deferred Share Units become settleable when she ceases to be a director or at a future date she previously specified. Upon settlement, each unit converts into one share of Bristol Myers Squibb common stock, according to the terms described.